Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice | Scientific Reports
Taking on Glioblastoma Through Translational Research: 4 Promising Bench-to-Bedside Initiatives – Consult QD
Ruxolitinib Phosphate Datasheet
Significant inhibitory effect of ruxolitinib in vivo. (A) Flow chart of... | Download Scientific Diagram
Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma | Nature Communications
JCI - Immunostimulatory bacterial antigen–armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy
Cancers | Free Full-Text | Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis | HTML
Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice | Scientific Reports
Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance | Science Translational Medicine
Inhibition of tumor growth and angiogenesis of tamoxifen‑resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor
JCI - Immunostimulatory bacterial antigen–armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy
TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance - ScienceDirect
Ruxolitinib Plus Radiation and Temozolomide for Newly Diagnosed Grade III Gliomas and Glioblastoma | PracticeUpdate
Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice | Scientific Reports
Cancers | Free Full-Text | Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies? | HTML
Combination of VSV-GP and ruxolitinib enhances virus replication in the... | Download High-Quality Scientific Diagram
A STAT3-based gene signature stratifies glioma patients for targeted therapy | Nature Communications
Can immunotherapy tackle glioblastoma?
Ruxolitinib (INCB018424) is an Orally Active JAK1 and JAK2 Inhibitor - Network of Cancer Research
The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway
Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy - ScienceDirect
Lineage and Spatial Mapping of Glioblastoma-associated Immunity | bioRxiv
The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway
Perspective of mesenchymal transformation in glioblastoma | Acta Neuropathologica Communications | Full Text
Targeting the JAK/STAT pathway in solid tumors
Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice | Scientific Reports
